You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lung Cancer Squamous Cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Squamous Cell Trial in London (Electrocautery Ablation (EC))

Terminated
  • Lung Cancer Squamous Cell
  • Electrocautery Ablation (EC)
  • London, United Kingdom
    UCLH
Oct 27, 2022

Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)

Recruiting
  • Lung Cancer Squamous Cell
  • +3 more
  • Boston, Massachusetts
  • +2 more
Jan 9, 2023

Advanced Squamous Non Small Cell Lung Cancer Trial (AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel)

Not yet recruiting
  • Advanced Squamous Non Small Cell Lung Cancer
  • AK112, Carboplatin, Paxlitaxel
  • Tislelizumab, Carboplatin, Paxlitaxel
  • (no location specified)
Apr 21, 2023

Advanced Squamous Non-Small-Cell Lung Cancer Trial (Trilaciclib, Carboplatin, Paclitaxel)

Not yet recruiting
  • Advanced Squamous Non-Small-Cell Lung Cancer
  • (no location specified)
Jun 11, 2023

Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)

Not yet recruiting
  • Sinonasal Cancer
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 5, 2023

Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • EGFR Positive Non-small Cell Lung Cancer
  • Toripalimab plus Chemotherapy
  • (no location specified)
Jul 28, 2023

Lung Cancer Trial (Cadonilimab)

Not yet recruiting
  • Lung Cancer
  • (no location specified)
Mar 23, 2023

NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Ivonescimab Injection
  • Pembrolizumab Injection
  • (no location specified)
Jun 9, 2023

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,

Not yet recruiting
  • Advanced Lung Squamous Cell Carcinoma
  • low-dose radiation therapy and stereotactic body radiation therapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Nov 13, 2023

PARP Inhibitor for Esophageal Squamous Cell Carcinoma Trial (Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only

Not yet recruiting
  • PARP Inhibitor for Esophageal Squamous Cell Carcinoma
  • Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
  • (no location specified)
Sep 24, 2023

Progression of Invasive Squamous Cell Carcinoma

Recruiting
  • Carcinoma, Squamous Cell
  • +10 more
  • DNA Extraction
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Sep 27, 2022

Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)

Not yet recruiting
  • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 20, 2023

NSCLC Trial in Chongqing (procedure, drug, radiation)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • bronchial artery interventional therapy
  • +3 more
  • Chongqing, Chongqing, China
    Daping Hospital, Third Military Medical University
May 27, 2023

Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung Trial in Guangzhou (SI-B001, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Adenocarcinoma
  • Squamous Cell Carcinoma of Lung
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 5, 2023

Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung

Recruiting
  • Lung Cancer Adenocarcinoma
  • +2 more
    • Sohag, Egypt
      Faculty of Medicine, Sohag University
    Jan 27, 2022

    NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)

    Recruiting
    • Non-small Cell Lung Cancer
    • Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
    • Wuhan, Hubei, China
      Union hospital
    Feb 20, 2023

    Lung Cancer Trial in Tampa, Columbus (Carboplatin, Paclitaxel, AZD1775)

    Active, not recruiting
    • Lung Cancer
    • Tampa, Florida
    • +1 more
    Feb 2, 2023

    Lung Cancer Squamous Cell Trial in Stuttgart, Tuebingen (CC-1 and Toczilizumab)

    Recruiting
    • Lung Cancer Squamous Cell
    • CC-1 and Toczilizumab
    • Stuttgart, BW, Germany
    • +1 more
    Feb 2, 2022

    NSCLC Trial in Pittsburgh (M1774, Cemiplimab)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Pittsburgh, Pennsylvania
      UPMC Cancer Center
    May 22, 2023

    NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Feb 16, 2023

    Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma Trial in

    Recruiting
    • Advanced Head and Neck Squamous Cell Carcinoma
    • +14 more
    • Laboratory Biomarker Analysis
    • +3 more
    • Indianapolis, Indiana
    • +4 more
    Aug 19, 2022

    Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)

    Active, not recruiting
    • Non-squamous Non-small-cell Lung Cancer
    • Brain Metastases
    • Guangzhou, Guangzhou, China
      Li-Kun Chen
    Nov 13, 2022

    NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)

    Completed
    Has Results
    • Non-Small Cell Lung Cancer
    • Brain Neoplasms
    • (no location specified)
    Dec 9, 2022

    Non Squamous Non Small Cell Lung Cancer Trial in Korea, Republic of (Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin)

    Not yet recruiting
    • Non Squamous Non Small Cell Lung Cancer
    • Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
    • Anam, Korea, Republic of
    • +7 more
    May 1, 2023